Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Two lawsuits filed Wednesday in the D.C. Circuit Court of Appeals mark the beginning of a rocky legal road for the Environmental Protection Agency following its reversal of a 2009 rule underpinning ...

The Trump administration in recent weeks has shifted its immigration enforcement rhetoric and tactics following the deaths of two U.S. citizens in Minnesota.

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Recursive, agent-driven intelligence promises extraordinary gains, but it also introduces risks that scale faster than human oversight, governance, and intuition. The challenge ahead is not whether ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recent victories by Democratic gubernatorial candidates in New Jersey and Virginia and for seats on the Georgia Public Service Commission have led outlets like Politico to brand the outcomes as the ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...